Compare SNDX & SAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNDX | SAM |
|---|---|---|
| Founded | 2005 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Beverages (Production/Distribution) |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.1B |
| IPO Year | 2016 | 1995 |
| Metric | SNDX | SAM |
|---|---|---|
| Price | $20.92 | $198.31 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 12 | 10 |
| Target Price | $36.92 | ★ $246.78 |
| AVG Volume (30 Days) | ★ 2.1M | 161.6K |
| Earning Date | 11-03-2025 | 10-23-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.12 |
| EPS | N/A | ★ 8.25 |
| Revenue | $111,304,000.00 | ★ $1,981,609,000.00 |
| Revenue This Year | $620.14 | N/A |
| Revenue Next Year | $115.42 | $0.75 |
| P/E Ratio | ★ N/A | $24.61 |
| Revenue Growth | ★ 595.65 | N/A |
| 52 Week Low | $8.58 | $185.34 |
| 52 Week High | $21.22 | $321.37 |
| Indicator | SNDX | SAM |
|---|---|---|
| Relative Strength Index (RSI) | 67.94 | 48.11 |
| Support Level | $20.00 | $190.71 |
| Resistance Level | $21.22 | $206.82 |
| Average True Range (ATR) | 0.93 | 5.62 |
| MACD | 0.03 | 1.38 |
| Stochastic Oscillator | 89.69 | 50.37 |
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
Boston Beer is a top player in high-end malt beverages and adjacent categories in the US, with strong positions in craft beer, flavored malt beverages, hard cider, and hard seltzer. The bulk of volume and revenue is concentrated in four brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly. Beverages are produced using a hybrid model leveraging both in-house capacities and third-party breweries through contract arrangements. While the firm is required to use distributors to reach end markets, including retailers and on-premises operators, it also employs 500 internal sales representatives to educate the market about its products. The firm generates almost all sales in the US.